NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma

Inclusion Criteria: * Newly diagnosed oligodendroglioma (oligo) (low grade oligo, low grade mixed oligoastrocytoma, anaplastic oligo, anaplastic mixed oligo) by histology and or molecular classification * Surgically sub-total or unresectable tumors, i.e. in insula, including but not limited to the insula and received standard of care (SOC) radiation * Historical pathological tissue evidence of high risk oligo (low grade oligo, low grade mixed oligoastrocytoma, anaplastic oligo, anaplastic mixed oligo) by histology and or molecular classification * 1p and 19q deletion status known * IDH 1 \& 2 mutations status known * MGMT status known * Karnofsky equal or greater than 70 * Life expectancy at least 3 months * Participants of childbearing age must use effective contraception * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months) * Ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * Actively participating in another clinical treatment trial * Tumor progression after radiation * Pregnant * Has implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other implanted electronic devices in the brain * Documented clinically significant cardiac arrhythmias * Infra-tentorial tumor